Open AccessFrequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia
Author(s) -
Roya Nazmabadi,
Fatemeh Taheri,
Mohammad-Alibeigi Faramarz,
Milad SabzevaryGhahfarokhi,
MohammadJavad Sanaei,
Najmeh Salehi-Vanani,
Yousef Mirzaei,
Nader Bagheri
Publication year - 2020
Publication title -
african health sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.391
H-Index - 44
eISSN - 1729-0503
pISSN - 1680-6905
DOI - 10.4314/ahs.v20i3.31
Subject(s) - cd19 , medicine , regulatory b cells , prostate cancer , immune system , interleukin 10 , hyperplasia , prostate , immunohistochemistry , cancer , immunology
Background: The function of the immune system in prostate cancer (PC) might promote carcinogenesis. PC is a common cancer in men. Regulatory B cells (Bregs) are a new subtype of B cells that have suppressive roles in the immune system. Inter- leukin-10 (IL-10) is a dominant mediator of immune suppression released by Bregs.
Objective: The purpose of this research was to examine the frequency of CD19+IL10+ B cells and IL-10 mRNA expression in patients with PC compared to patients with benign prostatic hyperplasia (BPH).
Methods: Forty paraffin tissue samples from patients with PC and 32 paraffin tissue samples from patients with BPH were en- tered in this study. The immunohistochemistry staining was used to evaluate the pattern expression of CD19 and IL-10 markers. IL-10 mRNA expression in fresh tissue was determined by real time-polymerase chain reaction (RT-PCR).
Results: The frequency of CD19+IL-10+ B cells and IL-10 mRNA expression in PC patients were significantly higher than patients with BPH. Also, there was no meaningful relationship between the frequency of IL-10+CD19+ B cells and gleason scores in patients with PC.
Conclusions: Our findings suggested that frequency of IL-10+CD19+ B cells correlates with progressive stage of PC.
Keywords: Prostate cancer; benign prostatic hyperplasia; IL-10+CD19+ B cells.